AN2 Therapeutics, Inc. Announces 2024 Annual Meeting of Stockholders on June 19, 2024
Ticker: ANTX · Form: DEF 14A · Filed: Apr 26, 2024 · CIK: 1880438
Sentiment: neutral
Topics: AN2 Therapeutics, Annual Meeting, Proxy Statement, Director Election, Auditor Ratification
TL;DR
<b>AN2 Therapeutics, Inc. is holding its 2024 Annual Meeting on June 19, 2024, with key proposals including director elections and auditor ratification.</b>
AI Summary
AN2 Therapeutics, Inc. (ANTX) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. AN2 Therapeutics, Inc. will hold its 2024 Annual Meeting of Stockholders on June 19, 2024, at 8:00 a.m. Pacific Time. The meeting will take place at the company's offices located at 1800 El Camino Real, Suite D, Menlo Park, California 94027. Stockholders will vote on the election of three Class II directors: Margaret FitzPatrick, Patricia Martin, and Melvin Spigelman, M.D. The agenda includes ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm. A proposal to amend and restate the certificate of incorporation for officer exculpation is also on the agenda.
Why It Matters
For investors and stakeholders tracking AN2 Therapeutics, Inc., this filing contains several important signals. The annual meeting is a critical governance event where shareholders exercise their voting rights on board composition and auditor selection. The proposed amendment to the certificate of incorporation regarding officer exculpation could impact director and officer liability protections.
Risk Assessment
Risk Level: low — AN2 Therapeutics, Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting and does not contain significant new financial or operational information that would indicate high risk.
Analyst Insight
Stockholders should review the director nominees and proposals carefully before casting their votes for the upcoming annual meeting.
Key Numbers
- June 19, 2024 — Annual Meeting Date (Date of the 2024 Annual Meeting of Stockholders)
- 8:00 a.m. Pacific Time — Meeting Time (Time of the 2024 Annual Meeting of Stockholders)
- 3 — Director Nominees (Number of Class II directors to be elected)
Key Players & Entities
- AN2 Therapeutics, Inc. (company) — Registrant
- June 19, 2024 (date) — Date of Annual Meeting
- Margaret FitzPatrick (person) — Director Nominee
- Patricia Martin (person) — Director Nominee
- Melvin Spigelman, M.D. (person) — Director Nominee
- PricewaterhouseCoopers LLP (company) — Independent Registered Public Accounting Firm
- Menlo Park, California (location) — Company Address
- 1800 El Camino Real, Suite D (address) — Company Address
FAQ
When did AN2 Therapeutics, Inc. file this DEF 14A?
AN2 Therapeutics, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 26, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by AN2 Therapeutics, Inc. (ANTX).
Where can I read the original DEF 14A filing from AN2 Therapeutics, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by AN2 Therapeutics, Inc..
What are the key takeaways from AN2 Therapeutics, Inc.'s DEF 14A?
AN2 Therapeutics, Inc. filed this DEF 14A on April 26, 2024. Key takeaways: AN2 Therapeutics, Inc. will hold its 2024 Annual Meeting of Stockholders on June 19, 2024, at 8:00 a.m. Pacific Time.. The meeting will take place at the company's offices located at 1800 El Camino Real, Suite D, Menlo Park, California 94027.. Stockholders will vote on the election of three Class II directors: Margaret FitzPatrick, Patricia Martin, and Melvin Spigelman, M.D..
Is AN2 Therapeutics, Inc. a risky investment based on this filing?
Based on this DEF 14A, AN2 Therapeutics, Inc. presents a relatively low-risk profile. The filing is a routine proxy statement for an annual meeting and does not contain significant new financial or operational information that would indicate high risk.
What should investors do after reading AN2 Therapeutics, Inc.'s DEF 14A?
Stockholders should review the director nominees and proposals carefully before casting their votes for the upcoming annual meeting. The overall sentiment from this filing is neutral.
Risk Factors
- General Disclosure [low — regulatory]: The filing is a routine proxy statement (DEF 14A) for an annual meeting of stockholders.
Key Dates
- 2024-06-19: Annual Meeting of Stockholders — Key date for shareholder voting on corporate matters.
- 2024-04-26: Filing Date — Date the Definitive Proxy Statement was filed with the SEC.
Glossary
- DEF 14A
- Definitive Proxy Statement (This filing type indicates the company is providing its final proxy materials to shareholders for an upcoming meeting.)
- Class II directors
- Directors elected for a specific term, typically part of a staggered board structure. (Relevant to understanding the board composition and election process.)
- Certificate of Incorporation
- The foundational document of a corporation, outlining its structure and powers. (Amendments to this document can significantly alter corporate governance and shareholder rights.)
- Officer Exculpation
- Provisions that shield officers from personal liability for certain breaches of duty. (Impacts the potential legal exposure of corporate officers.)
Filing Stats: 4,736 words · 19 min read · ~16 pages · Grade level 13.6 · Accepted 2024-04-26 16:15:11
Filing Documents
- antx-def14a-2023.htm (DEF 14A) — 804KB
- img188362103_0.jpg (GRAPHIC) — 15KB
- img188362103_1.jpg (GRAPHIC) — 4KB
- img188362103_2.jpg (GRAPHIC) — 4KB
- img188362103_3.jpg (GRAPHIC) — 1694KB
- img188362103_4.jpg (GRAPHIC) — 788KB
- 0000950170-24-049148.txt ( ) — 3996KB
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 15 Executive Officers Summary Compensation Table Narrative to Summary Compensation Table Outstanding Equity Awards as of December 31, 2023 Other Compensation and Benefits 401(k) Plan Emerging Growth Company Status Equity Compensation Plan Information Indemnification Hedging and Pledging Policies COMPENSATION OF NON-EMPLOYEE DIRECTORS 23 Non-Employee Director Compensation Policy Limitation of Liability and Indemnification BENEFICIAL OWNERSHIP OF SHARES OF COMMON STOCK 26 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 29 License Agreements March 2022 IPO Participation Investors’ Rights Agreement Indemnification Agreements Related Person Transaction Policy Director Independence PROPOSALS REQUIRING YOUR VOTE 31 Proposal 1 – Election of Class II Directors Number of Directors; Board Structure Nominees Recommendation of our Board Proposal 2 – Ratification of Independent Registered Public Accounting Firm Audit and Non-Audit Fees Policy on Audit Committee Pre-Approval and Permissible Non-Audit Services of Independent Registered Public Accounting Firm Recommendation of our Board Proposal 3 – Amendment and Restatement of Certificate of Incorporation to Provide for the Exculpation of Officers Proposed Amendment and Restatement of the Certificate of Incorporation Recommendation of our Board AUDIT COMMITTEE REPORT 33 TRANSACTION OF OTHER BUSINESS 35 REQUIREMENTS, INCLUDING DEADLINES, FOR SUBMISSION OF PROXY PROPOSALS, NOMINATION OF DIRECTORS AND OTHER BUSINESS OF STOCKHOLDERS 35 HOUSEHOLDING OF ANNUAL MEETING MATERIALS 35 DELINQUENT SECTION 16(A) REPORTS 36 iv OTHER MATTERS 36 Fiscal Year 2023 Annual Report and SEC Filings v AN2 Therapeutics, Inc. 1800 El Camino Real, Suite D Menlo Park, California 94027 PROXY STATEMENT QU ESTIONS AND ANSWERS Why am I receiving these proxy materials? The Board of Director